Table 1.
Clinical Characteristics and Marker Expression of the Studied Lesions
| Characteristic | CRC | HGD | HP | LGD | Total | P |
|---|---|---|---|---|---|---|
| Mean Age (Range) | 65.0 (31–84) | 58.1 (30–75) | 57.6 (28–79) | 57.1 (29–76) | 60.0 (28–84) | |
| Age (Y) | ||||||
| ≤65 | 23 (46.0%) | 19 (65.5%) | 25 (83.3%) | 36 (81.8%) | 103 (67.3%) | <0.001 |
| >65 | 27 (54.0%) | 10 (34.5%) | 5 (16.7%) | 8 (18.2%) | 50 (32.7%) | |
| Sex | ||||||
| Men | 30 (60.0%) | 19 (65.5%) | 21 (70.0%) | 27 (61.4%) | 97 (63.4%) | 0.814 |
| Women | 20 (40.0%) | 10 (34.5%) | 9 (30.0%) | 17 (38.6%) | 56 (36.6%) | |
| Location | ||||||
| Right side | 11 (22.0%) | 16 (55.2%) | 18 (60.0%) | 25 (56.8%) | 70 (45.8%) | 0.020 |
| Left side | 45 (90.0%) | 24 (82.8%) | 19 (63.3%) | 31 (70.5%) | 119 (77.8%) | |
| Markers | ||||||
| PD-1 high | 24 (48.0%) | 5 (17.2%) | 0 (0.0%) | 7 (15.9%) | 36 (23.5%) | <0.001 |
| PD-1 low | 26 (52.0%) | 24 (82.8%) | 30 (100.0%) | 37 (84.1%) | 117 (76.5%) | |
| PD-L1 high | 21 (42.0%) | 11 (37.9%) | 1 (3.3%) | 3 (6.8%) | 36 (23.5%) | <0.001 |
| PD-L1 low | 29 (58.0%) | 18 (62.1%) | 29 (96.7%) | 41 (93.2%) | 117 (76.5%) | |
| XRCC1 high | 28 (56.0%) | 5 (17.2%) | 1 (3.3%) | 10 (22.7%) | 44 (28.8%) | <0.001 |
| XRCC1 low | 22 (44.0%) | 24 (82.8%) | 29 (96.7%) | 34 (77.3%) | 109 (71.2%) | |
| FOXP3 high | 35 (70.0%) | 7 (24.1%) | 1 (3.3%) | 8 (18.2%) | 51 (33.3%) | <0.001 |
| FOXP3 low | 15 (30.0%) | 22 (75.9%) | 29 (96.7%) | 36 (81.8%) | 102 (66.7%) | |
| CD4 high | 34 (68.0%) | 16 (55.2%) | 3 (10.0%) | 15 (34.1%) | 68 (44.4%) | <0.001 |
| CD4 low | 16 (32.0%) | 13 (44.8%) | 27 (90.0%) | 29 (65.9%) | 85 (55.6%) | |
| XRCC1 rs25487 status | ||||||
| Wild | 33 (66.0%) | 13 (44.8%) | 12 (40.0%) | 19 (43.2%) | 77 (50.3%) | 0.059 |
| Mutant | 17 (34.0%) | 16 (55.2%) | 18 (60.0%) | 25 (56.8%) | 76 (49.7%) |
Note: Bold values, the statistically significant (P value < 0.05).